Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
FDA approves Wegovy pill for weight loss: What to know - 2Spain breaks jobs record with 22 million Social Security contributors
- 3It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- 4Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- 5Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Eight Muslim nations condemn Israel's 'dangerous' new death penalty law
- Shelby County deputies charged with assault, placed on leave
- Instructions to Decide the Best SUV Size for Seniors
- What's Your Number one Superhuman Film Made?
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- Exemplary Fragrances: A Manual for Notorious Scents
- Czech Republic caps fuel prices amid Iran war energy crisis
- The 15 Most Motivating TED Discusses All Time
